Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

A slim-looking Elon Musk in a Santa suit with a revelation has set the social media on fire. Musk, the richest man in the world with a net worth of more than 470 billion Dollars, revealed that he ...

The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).